HIV/AIDS Drugs: March 2007 Archives

clinical trialsLOS ANGELES, CA -- March 6, 2007 -- Raltegravir could be a viable therapeutic option for people with highly drug-resistant strains of HIV, according to findings from 2 studies presented here at the 14th Conference on Retroviruses and Opportunistic Infections (CROI).

The drug inhibits the enzyme HIV-1 integrase, making it effective against multi-drug resistant strains of HIV-1 and particularly CCR5-tropic and CXCR4-tropic strains, said investigator David Cooper, MD, director, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.

In a presentation on February 28th, Dr. Cooper discussed the study -- Blocking integrase in treatment Experienced patients with a Novel Compound against HIV: MeRcK, MK-0518 (BENCHMRK)-1 -- which included patients in Europe, Asia/Pacific, and Peru.

About this Archive

This page is a archive of entries in the HIV/AIDS Drugs category from March 2007.

HIV/AIDS Drugs: February 2007 is the previous archive.

HIV/AIDS Drugs: April 2007 is the next archive.

Find recent content on the main index or look in the archives to find all content.


Powered by Movable Type 4.24-en